This article has been updated with additional comments from Natera management.

NEW YORK (GenomeWeb) – Natera reported after the close of the market on Wednesday that its second quarter 2015 revenues climbed 26 percent over the second quarter 2014.

The San Carlos, California-based molecular diagnostic company reported total revenue of $45.1 million in Q2, up from $35.8 million in Q2 2014. It beat analysts' average estimate of $42.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.